Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

ALX Oncology has won two FDA fast-track designations for its lead immuno-oncology drug. The Irish-American biotech picked up the speedy reviews for ALX148 as a first-line treatment for head and ...

Alexander's (ALX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...

Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset failed to meet the primary endpoints of two phase 2 trials and is scrapping ...

ALX Oncology Q1 2025 Highlights and Recent Developments ... and FOLFIRI in patients with second-line metastatic colorectal cancer. Announced encouraging final results from the Phase 1 trial ...